Latest Breaking News On - Hans gelderblom - Page 1 : comparemela.com

Extended Imatinib Maintenance Boosts Disease-Free Survival in High-Risk GIST

Extended Imatinib Maintenance Boosts Disease-Free Survival in High-Risk GIST
medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.

Charles bankheadHans gelderblomScandinavian sarcoma groupUniversity claude bernardLeiden university medical centerEuropean society for medical oncologyEuropean society for medical oncology virtual plenaryJean yves blayEuropean societyMedical oncologyMedpage todayMedical oncology virtual

Vimseltinib confers superior response rate in tenosynovial giant cell tumor

Vimseltinib confers superior response rate in tenosynovial giant cell tumor
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Mindy valcarcelHans gelderblomBymatthew shinkleVimseltinib deciphera pharmaceuticalsLeiden university medical centerDeciphera pharmaceuticals

Deciphera Pharmaceuticals (DCPH) MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor Met Primary Endpoint

Deciphera Pharmaceuticals (DCPH) MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor Met Primary Endpoint
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Steve hoerterHans gelderblomDrug administrationDeciphera pharmaceuticalsConnective tissue oncology societyDeciphera pharmaceuticals incEuropean medicines agencyMedical oncologyLeiden university medicalChief executive officerResponse evaluation criteriaSolid tumorsNew drug applicationMarketing authorisation applicationTreatment durationCutoff date

Vimseltinib Improves 25-Week ORR Vs Placebo in TGCT

Vimseltinib elicited a statistically significant and clinically meaningful improvement in 25-week overall response rate vs placebo in patients with tenosynovial giant cell tumor that was not amenable to surgery.

Hans gelderblomSteve hoerterDeciphera pharmaceuticalsConnective tissue oncology society annual meetingMedical oncologyLeiden university medical centerTissue oncology society annual meetingTenosynovial giant cell tumor

Debiopharm International SA: DEBIOPHARM SHARES ONCOLOGY PROGRAM UPDATES AT ASCO 2023 FOR NOVEL WEE1 INHIBITOR, AND FIRST-IN-CLASS CA IX THERANOSTIC APPROACH

Debiopharm will highlight diversified approaches and commitment to improving outcomes for patients with cancer at the 2023 American Society of Clinical Oncology Conference A poster presentation

United statesPrnewswire debiopharmHans gelderblomDarrenr feldmanStephanie lheureuxAngela zubelAmerican society of clinical oncology conferenceMd department of medicineHead of communicationsWeill cornell medical collegeMemorial sloan kettering cancer centerMd leiden university medical centerDepartment of medicineAmerican society of clinical oncologyUniversity health networkClinical oncology conference